Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312176
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-07
Brief Title:
A Study of Sacituzumab Tirumotecan MK-2870 as a Single Agent and in Combination With Pembrolizumab MK-3475 Versus Treatment of Physicians Choice in Participants With HRHER2- Unresectable Locally Advanced or Metastatic Breast Cancer MK-2870-010
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC